株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

EpiCast Report:血友病の疫学的予測

EpiCast Report: Hemophilia - Epidemiology Forecast to 2026

発行 GlobalData 商品コード 344637
出版日 ページ情報 英文 39 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.47円で換算しております。
Back to Top
EpiCast Report:血友病の疫学的予測 EpiCast Report: Hemophilia - Epidemiology Forecast to 2026
出版日: 2017年07月01日 ページ情報: 英文 39 Pages
概要

当レポートでは、世界の主要9ヶ国 (米国、ドイツ、フランス、イタリア、スペイン、英国、日本、アルゼンチン、中国) における血友病A・Bの発症状況と今後の見通しについて分析し、疾患の特徴や、現在の有病者の発症状況、今後10年間の有病件数の予測値などを調査・推計しております。

第1章 目次

第2章 イントロダクション

  • 疾患の概略
  • 関連分析
  • 刊行予定の関連分析

第3章 疫学的予測

  • 疾患の背景事情
  • リスク要因と共存症
  • 世界的な傾向
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法
  • 血友病Aの疫学的予測
    • 診断済みの有病者数
    • 診断済みの有病者数:年齢別
    • 診断済みの有病者数:男女別
    • 診断済みの有病者数 (年齢調整済み)
  • 血友病Bの疫学的予測
    • 診断済みの有病者数
    • 診断済みの有病者数:年齢別
    • 診断済みの有病者数:男女別
    • 診断済みの有病者数 (年齢調整済み)
  • 血友病A・Bの疫学的予測
    • 診断済みの有病者数
    • 診断済みの有病者数:男女別
  • 議論
    • 疫学的予測に関する考察
    • 分析の限界
    • 分析の強み

第4章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHCER151-17

Hemophilia is an X-linked hereditary bleeding disorder, characterized by impaired blood coagulation as a result of deficiencies in the production or function of coagulation factor VIII (FVIII) in hemophilia A or factor IX (FIX) in hemophilia B (Bolton-Maggs and Pasi, 2003). Because of the deficiency of coagulation factor, hemophilia patients have a tendency for bleeding in joints, muscles, soft tissues, and within mucous membranes, which can be either spontaneous or due to internal or external trauma, depending on the severity of the disease (CDC, 2017b; Mayo Clinic, 2014).

In the 7MM, epidemiologists forecast an increase in the diagnosed prevalent cases of hemophilia A and hemophilia B, from 51,627 diagnosed prevalent cases in 2016 to 52,566 diagnosed prevalent cases in 2026, with an Annual Growth Rate (AGR) of 0.18% during the forecast period. The US will have the highest number of diagnosed prevalent cases of hemophilia A and hemophilia B among the 7MM throughout the forecast period, while Spain will have the lowest.

Among the 7MM in 2016, the UK had the highest age-standardized diagnosed prevalence of hemophilia A in men with 20.36 cases per 100,000 population and in women with 0.60 cases per 100,000 population. The age-standardized diagnosed prevalence of hemophilia A in Germany was lowest in men with 9.61 cases per 100,000 population and in women with 0.28 cases per 100,000 population.

The report "EpiCast Report: Hemophilia - Epidemiology Forecast to 2026" provides an overview of the comorbidities and the global and historical trends for hemophilia in seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of hemophilia segmented by type (hemophilia A and hemophilia B), sex, and age (for all ages) in these markets. The diagnosed prevalent cases of hemophilia A and hemophilia B by severity and with inhibitors were also provided in the report.

Scope

  • The Hemophilia EpiCast Report provides an overview of the risk factors and global trends of hemophilia in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of diagnosed prevalent cases of hemophilia segmented by type (hemophilia A and hemophilia B), sex, and age (for all ages) in these seven markets.
  • The hemophilia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Hemophilia EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global hemophilia market.
  • Quantify patient populations in the global hemophilia market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for hemophilia therapeutics in each of the markets covered.
  • Identify the percentage of hemophilia prevalent cases by type.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 4
  • 1.2 List of Figures 4

2 Hemophilia: Executive Summary 5

  • 2.1 Related Reports 6
  • 2.2 Upcoming Reports 6

3 Epidemiology 7

  • 3.1 Disease Background 7
  • 3.2 Risk Factors and Comorbidities 8
  • 3.3 Global and Historical Trends 8
  • 3.4 Forecast Methodology 10
    • 3.4.1 Sources 10
    • 3.4.2 Forecast Assumptions and Methods 13
    • 3.4.3 Diagnosed Prevalent Cases 14
    • 3.4.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity 15
    • 3.4.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Inhibitors 18
  • 3.5 Epidemiological Forecast for Hemophilia A (2016-2026) 19
    • 3.5.1 Diagnosed Prevalent Cases of Hemophilia A 19
    • 3.5.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A 19
    • 3.5.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A 20
    • 3.5.4 Diagnosed Prevalent Cases of Hemophilia A by Severity 21
    • 3.5.5 Diagnosed Prevalent Cases of Hemophilia A with Inhibitors 22
  • 3.6 Epidemiological Forecast for Hemophilia B (2016-2026) 23
    • 3.6.1 Diagnosed Prevalent Cases of Hemophilia B 23
    • 3.6.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia B 23
    • 3.6.3 Sex -Specific Diagnosed Prevalent Cases of Hemophilia B 24
    • 3.6.4 Diagnosed Prevalent Cases of Hemophilia B by Severity 25
    • 3.6.5 Diagnosed Prevalent Cases of Hemophilia B with Inhibitors 27
  • 3.7 Epidemiological Forecast for Hemophilia A and Hemophilia B (2016-2026) 27
    • 3.7.1 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B 27
    • 3.7.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B 28
    • 3.7.3 Sex -Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B 29
    • 3.7.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity 30
    • 3.7.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors 31
  • 3.8 Discussion 32
    • 3.8.1 Epidemiological Forecast Insight 32
    • 3.8.2 Limitations of the Analysis 33
    • 3.8.3 Strengths of the Analysis 33

4 Appendix 35

  • 4.1 Bibliography 35
  • 4.2 About the Authors 37
    • 4.2.1 Epidemiologist 37
    • 4.2.2 Reviewers 37
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology 38
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy 38
  • 4.3 About GlobalData 39
  • 4.4 Contact Us 39
  • 4.5 Disclaimer 39

List of Tables

1.1 List of Tables

  • Table 1: Relationship of Bleeding Severity with Clotting Factor Level. 7
  • Table 2: Comorbidities for Hemophilia 8
  • Table 3: 7MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, Selected Years 2016-2026. 19
  • Table 4: 7MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, Selected Years 2016-2026. 23
  • Table 5: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, Selected Years 2016-2026. 28

List of Figures

1.2 List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, 2016 and 2026 6
  • Figure 2: 7MM, Age-Standardized Diagnosed Prevalence of Hemophilia A (Cases per 100,000 Population), All Ages, 2016 9
  • Figure 3: 7MM, Age-Standardized Diagnosed Prevalence of Hemophilia B (Cases per 100,000 Population), All Ages, 2016 10
  • Figure 4: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B 11
  • Figure 5: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity 12
  • Figure 6: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors 13
  • Figure 7: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2016 20
  • Figure 8: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2016 21
  • Figure 9: 7MM, Diagnosed Prevalent Cases of Hemophilia A by Severity, Both Sexes, All Ages, N, 2016 22
  • Figure 10: 7MM, Diagnosed Prevalent Cases of Hemophilia A with Inhibitors, Both Sexes, All Ages, N, 2016 22
  • Figure 11: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, 2016 24
  • Figure 12: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, 2016 25
  • Figure 13: 7MM, Diagnosed Prevalent Cases of Hemophilia B by Severity, Both Sexes, All Ages, N, 2016 26
  • Figure 14: 7MM, Diagnosed Prevalent Cases of Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2016 27
  • Figure 15: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2016 29
  • Figure 16: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, All Ages, N, 2016 30
  • Figure 17: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity, Both Sexes, All Ages, N, 2016 31
  • Figure 18: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2016 32
Back to Top